Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xencor (XNCR) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (48)	10/29/2014 3:17:34 PM
From: tuck	Respond to of 136

RIghto, thanks!

To: scaram(o)uche who wrote (48)	10/30/2014 10:54:43 AM
From: fitzdad55	Read Replies (1) \| Respond to of 136

I wouldn't jump to the conclusion that Ph2a data for 5871 in RA is going to be unfavorable. In fact, in wouldn't surprise me if the endpoints are met. What I don't understand are the options vested respectively with Amgen and Xencor in regard to 5871 for RA. If topline data is quite compelling (certainly a big "if") what would be the road ahead in RA for this therapy? It seems clear from Bassil's presentation and Q&A that Xencor will not pursue RA indication for 5871, but does this mean Amgen wouldn't pursue it now that 5871 is fully back in the hands of Xencor? It could be me, but I didn't get any clear indication of this in the recent presser!